Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees.
Latham & Watkins LLP advised 4D Molecular Therapeutics in the agreement with a Healthcare & Life Sciences team led by Bay Area partners Chris Hazuka and Mark Roeder.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.